P35.24 Evaluation of an Up-To-Date Knowledge Base to Aid in Interpreting Somatic Mutations Detected in NGS Testing of Lung Cancer

Routine clinical interpretation of somatic variants from next-generation sequencing (NGS) testing of cancer samples remains challenging due to evolving medical guidelines and increasingly complex multi-variant data. Results from the IASLC Global Survey on Molecular Testing in Lung Cancer presented last year at WCLC reported that 37% of those requesting and treating patients had trouble understanding molecular test results (Smeltzer et al., JTO 2019). We assessed the ability of a CE-IVD somatic variant interpretation tool, NAVIFY® Mutation Profiler*, to provide accurate and timely clinical content to aid in the interpretation of somatic variants in 904 lung cancer samples from publicly available datasets such as The Cancer Genome Atlas (TCGA).